A Randomized, Double-blinded, Active-controlled, Multicenter Phase 3 Clinical Trial and Open-label, Extension Study to Evaluate the Efficacy and Safety of AD-218 in Patients With Mixed Dyslipidemia
Latest Information Update: 10 Feb 2025
At a glance
- Drugs AD 218 (Primary)
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Sponsors Addpharma
- 05 Feb 2025 Planned End Date changed from 30 Jun 2025 to 30 Jun 2026.
- 05 Feb 2025 Planned primary completion date changed from 31 Mar 2025 to 31 Mar 2026.
- 29 Jan 2024 Planned End Date changed from 31 Oct 2024 to 30 Jun 2025.